Pouyan Famini is an Endocrinology/Metabolic physician affiliated with University of California, Los Angeles. OpenAlex indexes 20 publications with 428 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
15503 Ventura Blvd Ste 170
Encino, CA 914363145
Telephone
818-461-8148Provider last certified this registry record 4 Dec 2024.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20241 payment
- Abbott LaboratoriesProgram year20232 payments
- Novo Nordisk IncProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
92%Other drugs affecting bone structure and mineralization77%Romosozumab-aqqg100%Part B, office-administered≥33 patientsRANK Ligand Inhibitor14.9%Denosumab100%Part B, office-administered≥94 patientsMetabolism & gastrointestinal
4.3%GLP-1 receptor agonist1.5%Ozempic40%Trulicity28%Mounjaro27%Rybelsus3%Victoza 3-Pak2%Part D<11 patientsBiguanide (metformin)1%Metformin Hcl Er53%Metformin Hcl47%Part D≥91 patients+ 7 more classes in this area
Cardiovascular
1.8%Statin0.8%Rosuvastatin Calcium40%Atorvastatin Calcium40%Pravastatin Sodium17%Lovastatin3%Part D<11 patientsAngiotensin receptor blocker (ARB)0.3%Losartan Potassium56%Valsartan24%Olmesartan Medoxomil20%Part D<11 patients+ 10 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cardiovascular Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Journal of Clinical Gastroenterology
2025 - Clonally expanded, thyrotoxic effector CD8 <sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
Science Translational Medicine
2023 - Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
The Journal of Clinical Endocrinology & Metabolism
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Beth Karlan, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Jerome Engel, MD
University of California, Los Angeles
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”